Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream

Plain-language summary

This study investigated photodynamic therapy using 5-aminolevulinic acid nanoemulsion as a light-sensitizing cream for lentigo maligna, a type of early skin lesion. It enrolled patients with non-invasive lentigo maligna on the skin of the face, neck, or upper body. It was conducted in Phase 4 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Completed

Sponsor

Joint Authority for Päijät-Häme Social and Health Care

Intervention

5-aminolevulinic acid nanoemulsion

Start date

2/1/2016

Estimated completion

3/1/2018

Countries

Finland

Related genes

Locations

• Lahti, Finland

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with non-invasive lentigo maligna located in the skin of face, neck or upper body region

Exclusion Criteria:

* Biopsy shows invasive melanoma inside lentigo maligna lesion prior treatment
* Porphyria or solar dermatitis
* Allergy for photosensitizer (5-aminolaevulinic acid) used in study
* Pregnant or breastfeeding patients